Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 14, 2021; 27(10): 919-927
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.919
Table 2 Ongoing clinical trials investigating the combination of radiotherapy and immune checkpoint inhibitors against hepatocellular carcinoma
NCT number
Institution
Disease
Estimated enrollment
Phase
Primary endpoint
Intervention
NCT04167293China (Sun Yat-sen University Cancer Center)HCC with portal vein invasion 116II/III6-mo PFSSBRT + sintilimab vs SBRT
NCT03817736Hong Kong (Queen Mary Hospital)HCC33IINumber of patients eligible for curative surgical interventionsTACE/SBRT + ICI
NCT03203304United States (University of Chicago)Unresectable HCC50INumber of participants with adverse eventsNivolumab + SBRT vs nivolumab and ipilimumab + SBRT
NCT04611165South Korea (NCC)HCC with major vascular invasion50IIPFSNivolumab + EBRT
NCT03482102United States (MGH)Locally advanced/unresectable or metastatic HCC or biliary tract cancer70IIORRTremelimumab + durvalumab + RT
NCT03316872Canada (UHN)HCC progression after sorafenib30IIORRPembrolizumab + SBRT
NCT04547452China (West China Hospital)Metastatic HCC84IIPFSSBRT + sintilimab vs sintilimab
NCT04193696China (Guangxi Medical University)Advanced HCC39IIORRRT+ anti-PD-1 agent